ArticleInternational journal of immunopathology and pharmacology2017
Expression of Foxp3 and its prognostic significance in colorectal cancer.
Article in International journal of immunopathology and pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Comprehensive Analysis and Experimental Validation of HEPACAM2 as a Potential Prognosis Biomarker and Immunotherapy Target in Colorectal Cancer.Current gene therapy · 2025Article
- FOXP3 expression in esophageal squamous cell carcinoma : Implications for cetuximab sensitivity and therapeutic strategies.Wiener klinische Wochenschrift · 2024Article
- High density of FOXP3 predicts better prognosis in germinal and non-germinal centre diffuse large B-cell lymphoma.International journal of experimental pathology · 2023Article
- Muscarinic Acetylcholine Receptor M3 Expression and Survival in Human Colorectal Carcinoma-An Unexpected Correlation to Guide Future Treatment?International journal of molecular sciences · 2023Article
- Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.Journal of clinical medicine · 2023Review
- Regulatory T Cells but Not Tumour-Infiltrating Lymphocytes Correlate with Tumour Invasion Depth in Basal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2022Article
- The Role of FOXP3 on Tumor Metastasis and Its Interaction with Traditional Chinese Medicine.Molecules (Basel, Switzerland) · 2022Review
- Correlations between Circulating and Tumor-Infiltrating CD4Vaccines · 2022Article
- Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3BMC gastroenterology · 2022Article
- Alterations of DNA methylation were associated with the rapid growth of cortisol-producing adrenocortical adenoma during pregnancy.Clinical epigenetics · 2021Article
- LncRNA LINC00520 aggravates cell proliferation and migration in lung adenocarcinoma via a positive feedback loop.BMC pulmonary medicine · 2021Article
- Superpixel image segmentation of VISTA expression in colorectal cancer and its relationship to the tumoral microenvironment.Scientific reports · 2021Article
- Increased CD3Biology · 2021Article
- Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.Scientific reports · 2021Article
- The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.BMC cancer · 2021Article
- Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer.Oncogene · 2021Article
- FOXP3 promotes colorectal carcinoma liver metastases by evaluating MMP9 expression via regulating S-adenosylmethionine metabolism.Annals of translational medicine · 2020Article
- Prognostic value of FoxP3 and CTLA-4 expression in patients with oral squamous cell carcinoma.PloS one · 2020Article
- Downregulation ofOncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to explore the expression and clinical significance of Foxp3 in colorectal tumor cells. An immunohistochemistry assay was used to detect the expression of Foxp3 in 173 cases of colorectal cancer. The relationship between the clinicopathological factors and the prognosis of colorectal cancer was analyzed. The rate of positive Foxp3 expression in tumor cells was 89.7%. There were no significant differences between cases with and without expression of Foxp3 with regard to sex, age, primary cancer sites, and distal metastasis. The expression of Foxp3 was negatively correlated with lymph node metastasis and pathological tumor, node, metastasis (pTNM) stage in tumor cells ( P < 0.05), which reflects the depth of invasion. Foxp3 expression also had a positive correlation with the degree of differentiation ( P < 0.01). A high level of Foxp3 expression was observed more often in tumor cells compared to tumor-surrounding tissues ( P = 0.003). High expression of Foxp3 was also associated with longer overall and disease-free survival ( P ⩽ 0.001). Foxp3 expression in colorectal cancer cells correlates with many clinicopathological characteristics; moreover, high expression of Foxp3 may be a promising potential prognostic factor for patients with colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.